The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression

被引:8
作者
Chen, Hai-bing [1 ]
Lu, Jun-xi [1 ]
Li, Qing [1 ]
Bao, Yu-qian [1 ]
Tang, Jun-ling [1 ]
Lu, Hui-juan [1 ]
Xiang, Kun-san [1 ]
Jia, Wei-ping [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Endocrinol & Metab, Shanghai Diabet Inst, Shanghai 200233, Peoples R China
关键词
vascular endothelium growth factor; diabetes; irbesartan; albumin excretion rate; renin angiotensin system; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR; EXPRESSION; KIDNEY; MICROALBUMINURIA; PODOCYTES; MELLITUS; BLOCKADE;
D O I
10.1038/aps.2008.28
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: The aim of the present study was to explore whether renin angiotensin system (RAS) inhibitor can reduce the production of vascular endothelium growth factor (VEGF). Further, we sought to elucidate the correlation between VEGF level and certain clinical parameters, such as albumin excretion rate (AER), before and after treatment with angiotensin type 1 receptor blocker. Methods: We recruited 166 type 2 diabetic patients at various stages of diabetic nephropathy (DN) and 46 healthy control subjects for a cross-sectional study. We recruited another 42 hypertensive type 2 diabetic patients with microalbuminuria for a longitudinal study involving a 6-month irbesartan treatment protocol. Urinary VEGF (uVEGF) levels were determined using ELISA. Results: In the cross-sectional study, hypertensive type 2 diabetic patients who received RAS inhibitor presented lower uVEGF levels than those who did not receive the RAS inhibitor. Statistical analysis indicated that uVEGF level was independently correlated with the AER. In the longitudinal study involving the 6-month irbesartan treatment, we demonstrated that uVEGF levels decreased significantly in patients who achieved a 50% AER reduction (remission group, n = 32). In contrast, uVEGF levels remained unchanged in patients who did not exhibit a 50% AER reduction (nonremission group, n = 10). Furthermore, the change in uVEGF was significantly correlated with the change in AER (r = 0.65, P < 0.01) before and after 6 months of irbesartan treatment. This result held true even after we had adjusted for the decrease in average blood pressure. Conclusion: The protective effect of the RAS inhibitor in DN patients is associated with the suppression of VEGF. Accordingly, it may be possible to use uVEGF as a marker of DN progression. We suggest that uVEGF may be an important target for therapeutic intervention in the context of DN.
引用
收藏
页码:242 / 250
页数:9
相关论文
共 18 条
[1]   Podocyte-derived vascular endothelial growth factor mediates the stimulation of α3(IV) collagen production by transforming growth factor-β 1 in mouse podocytes [J].
Chen, S ;
Kasama, Y ;
Lee, JS ;
Jim, B ;
Marin, M ;
Ziyadeh, FN .
DIABETES, 2004, 53 (11) :2939-2949
[2]   Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody [J].
Flyvbjerg, A ;
Dagnæs-Hansen, F ;
De Vriese, AS ;
Schrijvers, BF ;
Tilton, RG ;
Rasch, R .
DIABETES, 2002, 51 (10) :3090-3094
[3]   Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: Effects of an ACE inhibitor and an angiotensin II receptor antagonist [J].
Kakizawa, H ;
Itoh, Y ;
Imamura, S ;
Matsumoto, T ;
Ishiwata, Y ;
Ono, Y ;
Yamamoto, K ;
Kato, T ;
Hayakawa, N ;
Oda, N ;
Goto, Y ;
Nagasaka, A ;
Senda, T ;
Itoh, M .
HORMONE AND METABOLIC RESEARCH, 2004, 36 (07) :458-464
[4]   Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy [J].
Kanesaki, Y ;
Suzuki, D ;
Uehara, G ;
Toyoda, M ;
Katoh, T ;
Sakai, H ;
Watanabe, T .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (02) :288-294
[5]   Effects on protein kinase C-β inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy [J].
Kelly, Darren J. ;
Buck, Danielle ;
Cox, Alison J. ;
Zhang, Yuan ;
Gilbert, Richard E. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 293 (02) :F565-F574
[6]   Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy [J].
Kim, NH ;
Oh, JH ;
Seo, JA ;
Lee, KW ;
Kim, SG ;
Choi, KM ;
Baik, SH ;
Choi, DS ;
Kang, YS ;
Han, SY ;
Han, KH ;
Ji, YH ;
Cha, DR .
KIDNEY INTERNATIONAL, 2005, 67 (01) :167-177
[7]   Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus [J].
Kim, NH ;
Kim, KB ;
Kim, DL ;
Kim, SG ;
Choi, KM ;
Baik, SH ;
Choi, DS ;
Kang, YS ;
Han, SY ;
Han, KH ;
Ji, YH ;
Cha, DR .
DIABETIC MEDICINE, 2004, 21 (06) :545-551
[8]   Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes [J].
Lee, EY ;
Shim, MS ;
Kim, MJ ;
Hong, SY ;
Shin, YG ;
Chung, CH .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2004, 36 (01) :65-70
[9]   Vascular endothelial growth factor in diabetic nephropathy [J].
Lenz, T ;
Haak, T ;
Malek, J ;
Gröne, HJ ;
Geiger, H ;
Gossmann, J .
KIDNEY & BLOOD PRESSURE RESEARCH, 2003, 26 (5-6) :338-343
[10]   A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation [J].
Levey, AS ;
Bosch, JP ;
Lewis, JB ;
Greene, T ;
Rogers, N ;
Roth, D .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :461-+